First Clinical Safety Study Starts For Newron's Evenamide
Phase III Expected To Start In 2021 For The Potential Add-On Schizophrenia Therapy
Executive Summary
Following safety issues raised by the US FDA, no toxicity concerns have emerged in preclinical studies of Newron’s candidate schizophrenia therapy, evenamide, and a clinical safety study has started to evaluate its CNS effects.